[177Lu]DOTA-anti-CD20: Labeling and pre-clinical studies

被引：18
作者：
Audicio, Paola F. [1 ]
Castellano, Gustavo [3 ]
Tassano, Marcos R. [1 ]
Rezzano, Maria E. [1 ]
Fernandez, Marcelo [1 ]
Riva, Eloisa [2 ]
Robles, Ana [1 ]
Cabral, Pablo [1 ]
Balter, Henia [1 ]
Oliver, Patricia [1 ]
机构：
[1] Univ Republica, Fac Ciencias, Ctr Invest Nucl, Dept Radiofarm, Montevideo 11400, Uruguay
[2] Hosp Clin Montevideo, Clin Hematol Prof Dra L Diaz, Montevideo, Uruguay
[3] Univ Nacl Cordoba, FaMAF, RA-5016 Cordoba, Argentina
来源：
APPLIED RADIATION AND ISOTOPES | 2011年 / 69卷 / 07期
关键词：
CD20; Non-Hodgkin Lymphoma; Lu-177; Radioimmunotherapy; IBRITUMOMAB TIUXETAN RADIOIMMUNOTHERAPY; LOW-GRADE; LYMPHOMA; I-131; DOTA;
D O I：
10.1016/j.apradiso.2011.01.026
中图分类号：
O61 [无机化学];
学科分类号：
070301 ; 081704 ;
摘要：
Anti-CD20 (Rituximab (R)), a specific chimeric monoclonal antibody used in CD20-positive Non-Hodgkin's Lymphoma, was conjugated to a bifunctional quelate (DOTA) and radiolabeled with Lu-177 through a simple method. [Lu-177]-DOTA-anti-CD20 was obtained with a radiochemical purity higher than 97%, and showed good chemical and biological stability, maintaining its biospecificity to CD20 antigens. Monte Carlo simulation showed high doses deposited on a spheroid tumor mass model. This method seems to be an appropriate alternative for the production of [Lu-177]-DOTA-anti-CD20 as therapeutic radiopharmaceutical. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码：924 / 928
页数：5
相关论文
共 20 条
  • [1] [Anonymous], Nuclear Decay Data in the MIRD Format
  • [2] BERGER KJ, 1963, METHODS COMPUTATIONA, V1, P135
  • [3] Bernhardt P, 2001, ACTA ONCOL, V40, P602
  • [4] Dosimetric comparison of radionuclides for therapy of somatostatin receptor-expressing tumors
    Bernhardt, P
    Benjegård, SA
    Kölby, L
    Johanson, V
    Nilsson, O
    Ahlman, H
    Forssell-Aronsson, E
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 51 (02): : 514 - 524
  • [5] The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity
    Breeman, WAP
    van der Wansem, K
    Bernard, BF
    van Gameren, A
    Erion, JL
    Visser, TJ
    Krenning, EP
    de Jong, M
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (02) : 312 - 315
  • [6] Coiffier B, 1998, BLOOD, V92, P1927
  • [7] On the preparation of a therapeutic dose of 177Lu-labeled DOTA-TATE using indigenously produced 177Lu in medium flux reactor
    Das, Tapas
    Chakraborty, Sudipta
    Banerjee, Sharmila
    Venkatesh, Meera
    [J]. APPLIED RADIATION AND ISOTOPES, 2007, 65 (03) : 301 - 308
  • [8] The radioisotope contributes significantly to the activity of radioimmunotherapy
    Davis, TA
    Kaminski, MS
    Leonard, JP
    Hsu, FJ
    Wilkinson, M
    Zelenetz, A
    Wahl, RL
    Kroll, S
    Coleman, M
    Goris, M
    Levy, R
    Knox, SJ
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (23) : 7792 - 7798
  • [9] In vitro characterization of 177Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study
    Forrer, Flavio
    Chen, Jianhua
    Fani, Melpomeni
    Powell, Pia
    Lohri, Andreas
    Mueller-Brand, Jan
    Moldenhauer, Gerhard
    Maecke, Helmut R.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 (09) : 1443 - 1452
  • [10] The mechanisms of action of rituximab in the elimination of tumor cells
    Johnson, P
    Glennie, M
    [J]. SEMINARS IN ONCOLOGY, 2003, 30 (01) : 3 - 8
12